These data indicate that short-term treatment with monoclonal anti-GREM1/2 antibodies at the onset of myocardial inflammation in TCRM mice provided protection against lethal inflammatory cardiomyopathy despite the persistence of high numbers of potentially cardiopathogenic CD4+ T cells. The gene discussed is CD4; the disease is inflammatory response.